British Columbia - Biotech Sector - Presented by Bhanu Rahoni - Sector Manager (India)

British Columbia, Canada

Your Gateway to North American business opportunities

Presented by:

Bhanu Rahoni

Sector Manager - BiotechnologyTechnology, Research & Innovation,British Columbia Trade & Investment Representative Office (Bangalore)

Gateway to North America

BC

AAA

AB

AAA SK

AA+

MB

AA ON

AA

QC

A+

NL A

PEI A

NS A+

NB AA-

Canada Overall AAA

Source: Standard & Poor's,

Provincial Credit Rating (Standard & Poor’s)

% change against Indian Rupee

OANDA bid rates, Economic Times Intelligence Unit.

Number of Immigrants to BC by Source2003-2007

50,593

2,659

2,774

6,819

7,185

8,980

9,679

12,334

17,604

25,653

53,726

0 10,000 20,000 30,000 40,000 50,000 60,000

Others

Japan

Pakistan

Iran

England

Taiwan

United States

South Korea

Philippines

India

China

Indian community in British Columbia

Reduced Taxes for Investment & Talent

B.C. residents pay the lowest provincial personal income tax in Canada for incomes up to $118,000

British Columbia’s provincial corporate income tax is currently 10.5 % (10 % in 2011). The federal corporate tax rate is 16.1 % (15 %by 2012). With IFC tax refund, total corporate income tax is now 16.1 % & will become 15 % from 2012: Lowest in G7

B.C. taxes businesses at a rate of 2.5 % on their first $500,000 of business income. Government intends to eliminate the small business income tax by April 1, 2012.

British Columbia’s combined federal and provincial corporate tax rate is lower than any jurisdiction in North America.

Personal tax rates are similarly competitive.

Biomedical R&D

Medical Devices

Vancouver, British Columbia **0.0% 21.7%

San Diego, California 35.0% 39.5%

San Jose, California 35.0% 41.4%

Seattle, Washington 35.1% 34.0%

*Income taxes, net of available tax credits, as a share of pre-tax income**R&D tax credits eliminate all income tax liabilities

Source: KPMG Competitive Alternatives Cost Model; Ministry of Small Business, Technology and Economic Development, 2009.

Effective Corporate Income Tax Rates in BioTech

Rank City CityCost Index

(Vancouver -100)

Effective Income Tax

rate

1 Vancouver 100 16.1%

2 Toronto 116 30.2%

3 Shanghai 127 25.0%

4 Chicago 128 35.0%

5San

Francisco 129 35.0%

6 New York 132 35.3%

2010 Mercer rating again places Vancouver at 4th place in “Quality of Living Survey”

Quality of Living: Mercer’s survey of 221 Cities

City Ranking

Vienna 1

Zurich 2

Geneva 3

Vancouver 4

World Cost of Living, 2009, Rank and Index: New York = 100)

Vancouver ranks 71Out of 143 cities in Mercer’s ranking

Rank 2009

Rank 2008 City Country

Score 2009

Score 2008

1 2 Tokyo Japan 143.7 127

2 11 Osaka Japan 119.2 110

3 1 Moscow Russia 115.4 142.4

4 8 Geneva Switzerland 109.2 115.8

5 6 Hong Kong Hong Kong 108.7 117.6

6 9 Zurich Switzerland 105.2 112.7

7 7 Copenhagen Denmark 105 117.2

8 22New York City USA 100 100

9 20 Beijing China 99.6 101.9

10 13 Singapore Singapore 98 111.3

Life Sciences in British Columbia is

Very DiverseForest Biotech

Agricultural Biotech

Marine BiotechBiopharma & DevicesIndustrial Biotech

BioProducts and BioEnergy

World-Class Research is the Basis of our Industry

Most commercially successful cluster in Canada Approx. 100 companies in virtually all therapeutic areas Particular strengths in:

Oncology Genomics Infectious diseases Neuroscience Regenerative medicine HIV/AIDS Cardiology Metabolic diseases Personalized medicine

Biopharmaceuticals = BC’s Most Established Life Sciences Sector

Biotechnology company concentration by regionRegion PercentageAlberta 8%British Columbia 30%Manitoba 2%New Brunswick 2%Newfoundland 1%Nova Scotia 4%Ontario 26%PEI 3%Quebec 20%Saskatchewan 4% *Source: Statistics for Canada, Canadian Lifesciences Database. Online source. (Last accessed January 2010

Link: http://www.biotech.ca/en/what-biotech-is/facts-figures.aspx

Maximum concentration in British Columbia

To name a few innovations from BC:

QLT’s “Visudyne” One of the most successful ophthalmology products ever

2005 worldwide sales topping $480M US.

Angiotech’s Coronary Stent

2005 sales of TAXUS totaled $2.69B US

• Ranked 9th in N.A. by The Scientist for generating high-quality, patentable scientific research – number one in Canada.

• Ranked 8th in N.A., by the Milken Institute and number one in Canada for its tech transfer and commercialization activities.

“Patent Powerhouse”

Selected BC Centers of Excellence in Health Research

• BC Cancer Agency• Genome Sciences Centre• Brain Research Centre, UBC• Prostate Centre, VGH• Blood Research Centre, UBC• HIV/AIDS Centre of Excellence, St. Paul’s• Centre for Molecular Medicine & Therapeutics• Providence Heart & Lung Institute, St. Paul’s• iCord Spinal Chord Research Centre• Centre for Drug Research and Development

• TRIUMF: Canada's National Laboratory for Particle and Nuclear Physics & Medicine

BC Company Partner Product

Angiotech Boston Scientific Taxus Stent

QLT Novartis Visudyne

Nexterra GE Energy Gasification Systems

Xenon Takeda Pain Product

Cardiome Astellas/MERCK Vernakalant

Aspreva Roche Cellcept

Xenon Novartis Obesity & Metabolic Disorders

Response Biomedical 3M Infectious Disease Tests

BC attracted top global partners

Explore Business Opportunities with British Columbia

CONTACT:

BC TIR office

#600/1, ‘Akshaya’ First Floor100 Feet Road, IndiranagarBangalore, India

+91 80 4116 1216+91 96861 91723